10-K: Dar Bioscience Faces Going Concern Doubt Amidst Pipeline Advances

Dar Bioscience reported a significant net loss increase in 2025 and faces substantial doubt about its ability to continue as a going concern, despite advancing its product pipeline and expanding commercial strategies.

Summary

• Net loss increased to $13.4 million in 2025 from $4.1 million in 2024, with an accumulated deficit of $188.7 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond Q4 2026, requiring additional capital.
• Stockholders' equity is expected to be below the Nasdaq $2.5 million threshold as of March 31, 2026, potentially leading to a delist determination.
• The company expanded its business model in March 2025 to include a dual-path approach: traditional FDA approval and Section 503B compounding.
• Commercialization of DARE to PLAY Sildenafil Cream began in December 2025, with revenue expected in Q2 2026.
• DARE to RESTORE vaginal probiotic suppositories (Flora Sync LF5) are expected to be commercially available in Q2 2026.
• DARE to RECLAIM estradiol progesterone intravaginal ring (a 503B compounded product) is targeted for prescription fulfillment in early 2027.
• Ovaprene, a hormone-free contraceptive, is in a pivotal Phase 3 clinical study, with enrollment ongoing and expected to complete in 2026.
• Sildenafil Cream, 3.6% (for FSAD), is preparing for Phase 3 clinical studies, but initiation is delayed pending FDA alignment and capital.
• The DARE-HPV program received up to $10 million in milestone-based payments from ARPA-H, with $7.5 million received to date, and FDA clearance for its Phase 2 study was received in February 2026.
• Bayer terminated its license agreement for Ovaprene in December 2025 due to strategic prioritization, requiring the company to seek a new commercialization partner.
• The company sold XACIATO royalty and milestone rights to XOMA for $22.0 million in April 2024, with future revenue contingent on reaching an $88.0 million threshold.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Dar Bioscience, marked by increasing losses, significant going concern doubt, and Nasdaq listing risks. While strategic shifts and grant funding offer some positives, the delays in key clinical programs and the termination of a major partnership underscore substantial operational and financial hurdles.

Positives

• Expanded business model to include Section 503B compounding and consumer health products, aiming for earlier market access and reduced reliance on dilutive capital.
• Initiated commercialization of DARE to PLAY Sildenafil Cream in December 2025, with revenue expected to commence in Q2 2026.
• DARE to RESTORE vaginal probiotic suppositories (Flora Sync LF5) are expected to become commercially available in Q2 2026.
• Ovaprene's pivotal Phase 3 clinical study enrollment is ongoing and expected to complete in 2026.
• The Ovaprene study's Data Safety Monitoring Board (DSMB) recommended continuation without modification in July 2025, identifying no new safety or tolerability concerns.
• FDA clearance for the DARE-HPV Phase 2 clinical study was received in February 2026.
• Received $7.5 million of up to $10 million in milestone-based payments from ARPA-H for the DARE-HPV program.
• Received a $3.6 million grant installment in November 2025 to support Ovaprene Phase 3 and the identification of a new non-hormonal contraceptive candidate.
• Successfully completed an end-of-Phase 2 meeting with the FDA for Sildenafil Cream, aligning on key elements for its Phase 3 program.
• XACIATO received FDA approval in December 2021 and is available nationwide in the U.S. through Organon, benefiting from QIDP and Fast Track designations that extend data exclusivity until December 7, 2029.
• Net cash provided by financing activities significantly increased to $19.3 million in 2025 from $0.4 million in 2024.
• Increased interest earned on cash balances in 2025 and received approximately $0.3 million in employee retention credits for 2023 applications.

Negatives

• Net loss increased significantly to $13.4 million in 2025 from $4.1 million in 2024.
• Accumulated deficit grew to $188.7 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond Q4 2026.
• Stockholders' equity is expected to be substantially less than the Nasdaq $2.5 million threshold as of March 31, 2026, potentially leading to a delist determination.
• Bayer terminated its license agreement for Ovaprene in December 2025, necessitating a search for a new commercialization partner.
• The Sildenafil Cream Phase 2b RESPOND study did not meet its co-primary or secondary endpoints in the intent-to-treat (ITT) population.
• Initiation of the Sildenafil Cream Phase 3 study is delayed pending FDA alignment on protocol/statistical analysis plan and securing additional capital.
• NIH funding for the SBIR program (affecting DARE-PTB1) is frozen due to lack of reauthorization by Congress.
• Reliance on third parties for manufacturing, sales, marketing, and distribution introduces significant operational risks.
• Future revenue from XACIATO is contingent on reaching an $88.0 million threshold from XOMA, which may never be achieved.
• DARE to PLAY and DARE to RECLAIM are expected to be cash-pay only and not covered by insurance, potentially limiting market adoption.
• A cyber-attack in March 2023 resulted in a $0.4 million fraud loss, with only $0.2 million covered by insurance.

Risks

• Inability to raise substantial additional capital on favorable terms or at all, potentially forcing reduction or termination of operations.
• Failure to maintain Nasdaq Capital Market listing, which could lead to delisting and impair ability to raise capital.
• Limited operating history and a history of significant losses, making future prospects difficult to assess.
• Limited experience in the 503B compounding business and reliance on third parties for compounding and distribution.
• Risk of sildenafil citrate or other bulk drug substances being removed from the FDA's 503B list, prohibiting compounding.
• Failure to obtain FDA or foreign regulatory approval for product candidates on projected timelines or budgets.
• Clinical development is a lengthy, expensive process with inherently uncertain outcomes; failure in trials could materially harm the business.
• Delays or termination of clinical trials due to factors such as funding, regulatory issues, slow enrollment, adverse events, or supply chain disruptions.
• Loss or impairment of rights under in-license agreements for XACIATO or product candidates could disrupt development or commercialization.
• Dependence on strategic collaborations; failure to maintain existing or establish new ones could necessitate substantial additional capital.
• Delays and disruptions in manufacturing and supply of product candidates, including reliance on single-source suppliers.
• Lack of internal manufacturing, sales, marketing, or distribution infrastructure, requiring significant investment or third-party reliance.
• Failure to effectively execute product development, regulatory submission, and commercialization plans due to limited financial and human resources.
• Commercial success of XACIATO is outside of company control and depends on Organon's efforts and capabilities.
• Intense competition from generic products, compounding pharmacies, and large pharmaceutical companies in the women's health market.
• Failure to successfully obtain and maintain coverage and adequate reimbursement for products from government health care programs and other third-party payors.
• Inability to attract and retain key management and other personnel.
• Failure to identify and acquire or in-license additional product candidates or technologies, limiting growth potential.
• Inability to obtain and maintain sufficient intellectual property protection, allowing competitors to develop similar products.
• Patents for most products relate to specific formulations/uses, not active ingredients, potentially affording insufficient protection against competitors.
• Potential involvement in patent litigation or other intellectual property proceedings, leading to substantial costs or delays.
• Volatility in financial markets, geopolitical conflicts, public health emergencies, and other macroeconomic factors negatively impacting business and capital raising.
• Product liability lawsuits against the company could result in substantial liabilities and divert management attention.
• Future dilution to existing stockholders from sales and issuances of common stock to raise additional capital.
• Cyber-attacks, security breaches, loss of data, and other disruptions to information technology systems.
• Adverse impact of U.S. federal government funding and contracting policies, including potential freezes or terminations of grants.
• Achieving and maintaining market acceptance of 503B compounded drugs could be negatively impacted by perceived risks associated with such products.
• Uncertainty regarding the enforceability of forum selection provisions in the company's bylaws.

Future Outlook

The company expects to begin recording revenue from sales of DARE to PLAY and Flora Sync LF5 in Q2 2026 and targets DARE to RECLAIM availability in early 2027. Ovaprene Phase 3 enrollment is expected to complete in 2026, and the DARE-HPV Phase 2 study is planned for 2026. However, the Sildenafil Cream Phase 3 study initiation is delayed until FDA alignment and additional capital are secured, not anticipated in 2026. The company anticipates R&D expenses will remain the majority of operating expenses (pre-contra R&D) for at least the next 12 months and will need additional capital to fund operating needs through Q4 2026, facing substantial doubt about its ability to continue as a going concern and potential Nasdaq delisting due to expected low stockholders' equity.

Management Comments

• Our goal is to fulfill that need by bringing innovative products to market as soon as practicable, whether as FDA-approved therapies or through alternative regulatory pathways that enable earlier availability, such as Section 503B compounding.
• We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation.
• We believe the products positioning – science-backed, evidence-driven, and female-focused – sets a new benchmark for credibility in the female sexual wellness category. (referring to DARE to PLAY)
• By pursuing a balanced strategy that integrates short-term commercial execution with long-term R&D investment, we aim to reduce reliance on dilutive capital and build a financially sustainable model for innovation in women's health.
• We do not expect the expiration of the CRADA to have a negative impact on the Phase 3 study. (referring to Ovaprene CRADA)
• We do not expect the termination of the license agreement [with Bayer] to have a material impact on the ongoing pivotal Phase 3 study of Ovaprene.
• We do not plan to conduct the Phase 3 study [for Sildenafil Cream] until after we achieve alignment with the FDA on the protocol and statistical analysis plan and secure the capital required to conduct the Phase 3 study based on such protocol and statistical analysis plan. We do not anticipate initiating the first Phase 3 study in 2026 and cannot at this time reasonably predict when the study will commence.
• We believe a non-surgical, self-administered localized pharmaceutical approach that targets the virus itself rather than waiting for cellular changes to develop has the potential to redefine the treatment paradigm in cervical disease prevention. (referring to DARE-HPV)
• Our approach is to engage consultants with experience in varying specialties to help us develop our diverse portfolio of product candidates and bring to market 503B compounded products and consumer health products. We believe this approach enables us to access the expertise needed in a cost-efficient manner and without the need to rapidly increase the number of full-time employees and their associated costs.
• Based on our current analysis of the conditions described above, there is substantial doubt about our ability to continue as a going concern within the 12-month period from the issuance date of the accompanying consolidated financial statements.

Industry Context

StockSavvy.ai notes that Dar Bioscience's dual-path strategy, leveraging both traditional FDA approval and 503B compounding, is a response to the historically underfunded women's health sector, aiming for earlier market access and reduced reliance on dilutive capital. The focus on bio-identical hormones and non-surgical HPV treatments aligns with growing patient and provider demand for customized, less invasive, and evidence-based solutions in a market traditionally dominated by generic or off-label options. The termination of the Bayer agreement for Ovaprene highlights the challenges of maintaining large pharma collaborations in this evolving sector, while the ARPA-H funding for DARE-HPV signals increasing governmental interest in addressing critical unmet needs in women's health. The company's financial struggles, including a significant net loss and going concern doubt, reflect the high capital intensity and inherent risks of biotech R&D, particularly in a niche market that has historically seen lower investment compared to other healthcare sectors.

Comparison to Industry Standards

• Ovaprene's potential typical use contraceptive efficacy of approximately 86% to 91% approaches the approximately 93% typical use efficacy rate expected during the first year of use of current FDA-approved non-implanted, non-injected hormonal contraceptive methods (pills, patches and vaginal rings).
• Sildenafil Cream's Phase 1 study demonstrated significantly lower systemic exposure to sildenafil (geometric mean maximum plasma concentration of 5,262 pg/mL after 200 mg dose) compared to a 100 mg oral sildenafil dose administered to men (450,000 pg/ML), showing almost two orders of magnitude lower systemic exposure.
• DARE-HRT1's Phase 1 clinical trial showed similar steady-state concentrations of estradiol (E2) as seen with FDA-approved drug products for treatment of vasomotor symptoms and genitourinary symptoms of menopause.
• DARE-HRT1's Phase 1/2 study indicated systemic progesterone (P4) concentrations were all in the normal post-ovulatory range, which predicts endometrial protection, a key safety consideration for hormone therapy.
• DARE-PDM1's Phase 1 study results suggest vaginal dosing could lead to systemic diclofenac exposure approximately 1,000 times less than that seen from oral use.
• The company's strategy of engaging consultants rather than rapidly increasing full-time employees is a capital-efficient approach, contrasting with the larger internal R&D and commercial infrastructures of many competitors.
• The women's health sector has historically been underfunded, with only about one percent of healthcare research and innovation in the U.S. invested in female-specific conditions beyond oncology, highlighting the significant investment gap compared to other healthcare sectors.

Corporate Governance

Legal Proceedings

• As of the date of filing this report, there are no material pending legal proceedings to which the company is a party or to which any of its property is subject.

Related Party Transactions

• In January 2024, the company entered into a consulting agreement with its former Chief Financial Officer for a nine-month period, paying $31,667 per month and reimbursing up to $500 per month for health insurance premiums.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises, risk of losing investment due to going concern doubt, stock price volatility, and risk of delisting from Nasdaq. Future revenue from XACIATO is limited due to the royalty sale.
• Patients may benefit from earlier access to women's health solutions through 503B compounding (DARE to PLAY, DARE to RECLAIM, DARE to RESTORE) and potential new contraceptive options (Ovaprene, DARE-LARC1), but unmet needs for FSAD and HPV treatments persist.
• Employees may experience increased workload due to a small employee base, potential for burnout/turnover, and dependence on the company's ability to attract and retain key personnel. Staffing shortages could impact development timelines.
• Third-party payors face uncertainty regarding coverage and reimbursement for new products, especially compounded drugs (DARE to PLAY, DARE to RECLAIM) and novel treatments like Sildenafil Cream.
• Licensors and collaborators face risks related to the company's ability to meet obligations under license agreements, the impact of Bayer's termination on Ovaprene's commercialization, and reliance on Organon for XACIATO's commercial success.

Next Steps

• Continue to pursue various capital raising options, including the ongoing Regulation A offering.
• Actively pursue initiatives to increase stockholders' equity to meet Nasdaq listing requirements.
• Complete enrollment in the Ovaprene pivotal Phase 3 clinical study in 2026.
• Initiate the DARE-HPV Phase 2 clinical study in 2026.
• Achieve FDA alignment on protocol and statistical analysis plan for the Sildenafil Cream Phase 3 study.
• Secure additional capital to conduct the Sildenafil Cream Phase 3 study.
• Commence pharmacy dispensing and revenue recording for DARE to PLAY Sildenafil Cream in Q2 2026.
• Commercially launch DARE to RESTORE Flora Sync LF5 in Q2 2026.
• Target DARE to RECLAIM estradiol progesterone intravaginal ring availability in early 2027.
• Negotiate an agreement with a third party to commercialize Ovaprene if it receives marketing approval.
• Monitor the reauthorization of the SBIR program to resume DARE-PTB1 funding.
• Conduct additional manufacturing activities to commence Phase 1 studies for DARE-204 and DARE-214.
• Conduct Phase 2 clinical study for DARE-VVA1 after securing additional capital.
• Conduct Phase 1 clinical studies for DARE-FRT1 and DARE-PTB1 after securing additional capital.

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating 'substantial doubt about our ability to continue as a going concern' and anticipating a Nasdaq delist determination due to insufficient stockholders' equity. While there are promising pipeline assets and a new commercial strategy, the significant and increasing net losses, heavy reliance on external capital, and delays in critical Phase 3 trials for lead candidates (Sildenafil Cream) present overwhelming risks. The termination of the Bayer partnership for Ovaprene further complicates future commercialization. Given the high uncertainty and immediate financial threats, a seasoned investor would likely recommend selling to mitigate exposure to potential capital loss and delisting.

Keywords

Women's Health, Biotech, Pharmaceuticals, Contraception, Sexual Health, Menopause, Vaginal Health, Infectious Disease, Pelvic Pain, Fertility, FDA Approval, Clinical Trials, 10-K, Sildenafil Cream, Ovaprene, DARE-HPV, XACIATO, DARE to PLAY, DARE to RESTORE, DARE to RECLAIM, Going Concern, Nasdaq Listing, Grants, Royalty Monetization, Drug Development, Medical Device, Combination Product, Intellectual Property, 503B Compounding